Amgen Inc. closed 14.87% below its 52-week high of $346.85, which the company reached on July 25th.

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Amgen is set to release its second-quarter earnings next month, and analysts are projecting modest single-digit growth in ...

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

The biosimilars market is estimated to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% ...

The global gene therapy market is projected to grow at a significant CAGR of 20% from 2024 to 2029. This growth is driven by ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Amgen (AMGN) one of those stocks right now? A quick glance at ...

A phenotype-based profiling test can help predict whether a patient might respond better to one antiobesity medicine or ...

Ghana is witnessing a sharp increase in oncology or cancer incidences with approximately 27,385 new cases reported in 2022 ...

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Amgen, with a price target of $300.00. The company’s shares closed last Friday at $295.27. Schott covers the ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's policies. Health care stocks can often be a solid defensive play in an ...

US stocks put in solid gains on Thursday, with the S&P 500 and Nasdaq both settling at new record highs, following a raft of ...